Summary

Labiotech highlights eight emerging biotech companies advancing the next generation of antibody–drug conjugates (ADCs). While ADCs have matured into a validated therapeutic modality, limitations with toxicity, linker stability, and target selection have created opportunities for innovative newcomers. These companies—such as Adcendo, Adcentrx Therapeutics, Araris Biotech, Duality Biologics, MBrace Therapeutics, MediLink Therapeutics, and Tubulis—are refining linker chemistry, exploring new payload classes, and expanding the range of tumour types addressable by ADCs. The article profiles each company’s lead assets, clinical status, unique technology platforms, and recent financial milestones.

Why This Matters for the Life Sciences Sector

ADC development is undergoing a transformation driven by technical challenges in traditional designs—namely, limited payload diversity, target selection constraints, and off‑target toxicity. Emerging players are innovating across the entire molecule: antibody engineering, linker chemistry, and payload design. This next generation of ADCs is primed to expand into more solid tumours, addressing resistance mechanisms and improving safety profiles. With multiple candidates entering Phase 1/2 trials and major financings (e.g., Adcendo’s $135M Series B), this segment continues to attract investment, partnerships, and significant clinical interest.

Expert Insight from Origio Partners

Talent & Leadership Implications

• ADC innovation demands multidisciplinary expertise across chemistry, protein engineering, translational oncology, toxicology, and early clinical development.
• Companies advancing first‑in‑class linker technologies or novel payloads require leaders capable of coordinating complex CMC, BD, and regulatory pathways.
• As more ADCs progress through first‑in‑human studies, there is rising demand for early‑phase clinical strategists, medical leads, and biomarker‑driven translational hires.

What This Means for Hiring

• Startups scaling ADC platforms need leadership equipped to manage partnerships with major pharma companies—particularly in co‑development models common in oncology.
• Recruitment will grow across CMC, process development, bioconjugation chemistry, toxicology, regulatory affairs, and clinical operations.
• Organisations with novel ADC architectures require scientific-commercial hybrid leaders who understand both technology differentiation and market positioning.

How Origio Partners Supports Organisations in This Space

Origio Partners specialises in retained search for high‑growth biotechs and oncology innovators. As ADC technologies advance rapidly, we support companies in securing senior leaders and niche specialists in:

• Oncology research & translational leadership
• Bioconjugation chemistry and linker/payload development
• Clinical development and early‑phase oncology strategy
• CMC, process development, and commercial strategy for emerging platforms

Our global reach across the UK, Europe, and the US positions us to help companies build the integrated teams required to advance complex therapeutic modalities like ADCs.

Key Takeaways

• Eight biotech companies are leading the next wave of ADC innovation, focusing on difficult targets and improved payload/linker designs.
• Several candidates (e.g., Adcendo’s ADCE‑D01) are already in Phase 1/2 clinical development with regulatory designations and strong fundraising success.
• Innovation efforts aim to overcome toxicity, resistance, and efficacy limitations seen in older ADCs.
• Hiring demand is intensifying across translational research, CMC, early‑clinical leadership, and oncology portfolio strategy.